Sugi Predict

Sugi Predict / Compounds / SCHEMBL17401028

SCHEMBL17401028

SCHEMBL17401028

CCc1ncnc2cccnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.45
▸ PDE4A P27815 1/20 0.38
▸ HSP90AA1 P07900 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ PRMT5 O14744 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ GMNN O75496 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MMP2 P08253 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ MMP9 P14780 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ CCR1 P32246 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14314008 0.76 PDE4A (0.38) PDE4AHSP90AA1NPC1L3MBTL1PRMT5
SCHEMBL12014825 0.74 PRMT5 (0.41) PDE4AHSP90AA1NPC1L3MBTL1PRMT5
SCHEMBL21808761 0.74 RAB9A (0.49) EGFRNPC1L3MBTL1MAPTKDM4E
SCHEMBL19185218 0.74 PRMT5 (0.38) PDE4AHSP90AA1NPC1PRMT5MAPT
SCHEMBL13454691 0.74 HSP90AA1 (0.45) EGFRHSP90AA1NPC1L3MBTL1PRMT5
SCHEMBL21367400 0.74 PDE3B (0.37) MAPTKDM4ECCR1CCR5CCR8
SCHEMBL12560186 0.74 EGFR (0.49) EGFRHSP90AA1NPC1L3MBTL1PRMT5
SCHEMBL3237268 0.74 EGFR (0.45) EGFRHSP90AA1NPC1L3MBTL1MAPT
SCHEMBL30946645 0.74 EGFR (0.45) EGFRHSP90AA1NPC1L3MBTL1MAPT
SCHEMBL2614518 0.72 PI4KA (0.50) EGFRPDE4ANPC1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE INCYTE CORPORATION 2023-12-14 — — US disclosed
US-11787793-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-10-17 — — US disclosed
US-20230044941-A1 TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. 2023-02-09 — — US disclosed
US-20220194931-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-06-23 — — US disclosed
US-11339149-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2022-05-24 — — US disclosed
US-20210130347-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. 2021-05-06 — — US disclosed
US-20210107900-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-04-15 — — US disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 — — WO disclosed
WO-2020263967-A1 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 — — WO disclosed
US-20190282582-A1 PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2019-09-19 — — US disclosed
US-10328078-B2 Pteridine dione monocarboxylate transporter inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2019-06-25 — — US disclosed
US-9732088-B2 C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2017-08-15 — — US disclosed
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-04-27 — — US disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339149-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS EGFR 3005/4885PDE4A 2463/4885HSP90AA1 662/4885
US-20210107900-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS EGFR 3005/4885PDE4A 2463/4885HSP90AA1 662/4885
US-20220194931-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS EGFR 3005/4885PDE4A 2463/4885HSP90AA1 662/4885
US-20190282582-A1 PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS SLC16A1, SLC16A3, SLC16A7 EGFR 2486/4885PDE4A 2751/4885HSP90AA1 2945/4885
US-20210130347-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 EGFR 584/4885PDE4A 2968/4885HSP90AA1 3568/4885
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE2, BACE1, APP EGFR 897/4885PDE4A 3394/4885HSP90AA1 4398/4885
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE STING1, PDCD1LG2, CD274 EGFR 518/4885PDE4A 2010/4885HSP90AA1 873/4885
US-11787793-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS EGFR 3005/4885PDE4A 2463/4885HSP90AA1 662/4885
US-20230044941-A1 TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES CD274, PDCD1, PDCD1LG2 EGFR 1219/4885PDE4A 1899/4885HSP90AA1 3761/4885
US-10328078-B2 Pteridine dione monocarboxylate transporter inhibitors SLC16A1, SLC16A3, SLC16A7 EGFR 2486/4885PDE4A 2751/4885HSP90AA1 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.